Evidence and the Evolving Treatment Landscape for COVID-19 with Virus Neutralizing Antibodies

Target Audience

The primary intended audience for this education includes practicing US HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, registered nurses, and pharmacists.

Program Overview

“Evidence and the Evolving Treatment Landscape for COVID-19 with Virus Neutralizing Antibodies,” expert faculty will review the requirements and rationale for the FDA’s emergency use authorization (EUA), along with efficacy and safety data for NAbs and treatment combinations. This activity will also highlight practical strategies to identify those patients who can benefit from these treatment options.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Understand the rationale for and process by which the FDA issues an EUA for agents developed for the treatment of COVID-19
Recognize SARS-CoV-2-infected patients with mild to moderate COVID-19 who could benefit from NaBs treatments.
Faculty

Rebecca C. Keith, MD
Associate Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine
Interstitial Lung Disease Program
Autoimmune Lung Center
National Jewish Health

Jared J. Eddy, MD, MPhil, MSc
Assistant Professor Director of Infection Prevention & Antimicrobial Stewardship
Division of Mycobacterial & Respiratory Infections
Department of Medicine
National Jewish Health
BIO
LOCATION